Aurinia Pharmaceuticals Inc (AUPH) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. Welcome to the Irinia Pharmaceuticals' fourth quarter and full year 2025 conference call. Please be advised that a Q&A session will follow Irinia's prepared remarks, and we ask you please ask one question and one follow-up to return to the queue. I will now turn the call over to Peter Greenleaf, President and Chief Executive Officer of Irinia. Peter, please go ahead. Good morning. We want to thank you all for joining us today to discuss Arinia's fourth quarter and full year 2025 update. Joining me on the call today are Joe Miller, our Chief Financial Officer, and Dr. Greg Keenan, our Chief Medical Officer. On today's call, we will report fourth quarter and full year 2025 financial results and provide an update on recent business progress. During today's call, we may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. We are pleased to have delivered strong Lucana sales in 2025, growing at a rate of 25% year-over-year. And for 2026, we expect net product sales of $305 million to $315 million, up 12 to 16% compared to 2025. And with that introduction, I'd like to now turn the call over to Joe to review our financial results. Joe? Thank you, Peter. Total revenue for the fourth quarter of 2025 was $77.1 million, up 29% compared to $59.9 million for the same period of 2024. Net product sales of Loop Kindness for the fourth quarter of 2025 were $74.2 million, up 29% compared to $57.6 million in 2024. Net income for the fourth quarter of 2025 was $210.8 million, up 14,957% from $1.4 million in 2024. In the fourth quarter of 2025, the company recorded an income tax benefit of $175.1 million, primarily due to the r...